Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography

被引:73
|
作者
Miles, KA [1 ]
Griffiths, MR
Keith, CJ
机构
[1] Univ Sussex, Brighton & Sussex Med Sch, Div Clin & Lab Sci, Brighton BN7 3PB, E Sussex, England
[2] Queensland Univ Technol, Gardens Point Brisbane, Brisbane, Qld, Australia
[3] Wesley Res Inst, Brisbane, Qld, Australia
关键词
non-small cell lung cancer; tumour blood flow; glucose metabolism; tumour size; F-18-FDG;
D O I
10.1007/s00259-005-1932-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to undertake dual assessment of tumour blood flow and glucose metabolism in non-small cell lung cancer (NSCLC) using contrast-enhanced computed tomography (CE-CT) and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in order to assess how the relationships between these parameters vary with tumour size and stage. Methods: Tumour blood flow and glucose metabolism were assessed in 18 NSCLCs using quantitative CE-CT and FDG-PET respectively. Contrast enhancement and FDG uptake were both normalised to injected dose and patient weight to yield correspondingly the standardised perfusion value (SPV) and standardised uptake value (SUV). Tumour area was measured from conventional CT images. Results: The ratio of SUV to SVP and the metabolic - flow difference ( SUV - SVP) correlated with tumour size ( r= 0.56, p= 0.015 and r= 0.60 and p= 0.008 respectively). A metabolic flow difference of greater than 4 was more common amongst tumours of stages III and IV ( odds ratio 10.5; 95% confidence limits 0.24 - 32.1). A significant correlation between SUV and SPV was found only for tumours smaller than 4.5 cm(2) ( r= 0.85, p= 0.03). Conclusion: Blood flow - metabolic relationships are not consistent in NSCLC but depend upon tumour size and stage. Quantitative CE-CT as an adjunct to an FDG study undertaken using integrated PET-CT offers an efficient way to augment the assessment of tumour biology with possible future application as part of clinical care.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 50 条
  • [21] Complete pathological response to chemotherapy for non-small cell lung cancer demonstrated by gamma camera positron emission tomography
    Old, SE
    Gilligan, D
    Balan, KK
    Coulden, RAR
    CLINICAL ONCOLOGY, 2000, 12 (01) : 53 - 55
  • [22] Correlation between Circulating Tumor Biomarkers and Positron-Emission Tomography in Advanced Non-Small Cell Lung Cancer
    Genova, Carlo
    Rijavec, Erika
    Biello, Federica
    Barletta, Giulia
    Maggioni, Claudia
    Coco, Simona
    Vanni, Irene
    Truini, Anna
    Alama, Angela
    Buzzatti, Giulia
    Morbelli, Silvia
    Ferrarazzo, Giulia
    Bongioanni, Francesca
    Sambuceti, Gianmario
    Massollo, Michela
    Grossi, Francesco
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S358 - S358
  • [23] The Maximum Standardized Uptake Values on Positron Emission Tomography Predict Pathological Characteristics of Non-Small Cell Lung Cancer
    Koike, T.
    Shimizu, Y.
    Goto, T.
    Sato, S.
    Toyabe, S.
    Tsuchida, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S548 - S549
  • [24] Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer
    Duan, Xiao-Yi
    Wang, Wen
    Wang, Jian-Sheng
    Shang, Jin
    Gao, Jun-Gang
    Guo, You-Min
    BMC CANCER, 2013, 13
  • [25] The Ki-67 index and survival in non-small cell lung cancer: A review and relevance to positron emission tomography
    Pugsley, JM
    Schmidt, RA
    Vesselle, H
    CANCER JOURNAL, 2002, 8 (03) : 222 - 233
  • [26] Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer
    Eaton, Keith D.
    Romine, Perrin E.
    Martins, Renato G.
    Leblond, Antoine
    Carr, Laurie L.
    Vesselle, Hubert J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [27] Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer
    Bury, T
    Dowlati, A
    Paulus, P
    Corhay, JL
    Hustinx, R
    Ghaye, B
    Radermecker, M
    Rigo, P
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (11) : 2529 - 2534
  • [28] Importance of SUVmax threshold in positron emission tomography-computed tomography assessment of mediastinal and hilar lymph nodes in non-small cell lung cancer
    Yildiz, Oya
    Cangir, Ayten Kayi
    Kilic, Dalokay
    Yuksel, Cabir
    Enon, Serkan
    Kutlay, Hakan
    Akal, Murat
    Ozdemir, Nezih
    Kavukcu, Sevket
    Okten, Ilker
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2016, 24 (02): : 333 - 339
  • [29] Comparison of the diagnostic value of positron emission tomography and computed tomography for mediastinal lymph node metastatic involvement in patients with non-small cell lung cancer
    Bella, Mariusz
    Dancewicz, Maciej
    Swiniarska, Joanna
    Blawat, Przemyslaw
    Kowalewski, Janusz
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2008, 5 (03): : 292 - 295
  • [30] DIAGNOSTIC PERFORMANCE OF INTEGRATED POSITRON EMISSION TOMOGRAPHY/COMPUTER TOMOGRAPHY FOR MEDIASTINAL LYMPH NODES STAGING IN NON-SMALL CELL LUNG CANCER: A BIVARIATE SYSTEMATIC REVIEW AND META-ANALYSIS
    Lv, Yanling
    Yuan, Dongmei
    Wang, Ke
    Miao, Xiaohui
    Qian, Qian
    Wei, Shuzhen
    Zhu, Xixu
    Song, Yong
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1123 - S1123